GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer

GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic

开始日期2021-05-07

申办/合作机构

Galera Therapeutics, Inc.

NCT04476797

/ Terminated临床1/2期

GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)

GTI-4711-101 is a Phase I/II study of the safety of GC4711, its effect on in-field tumor response and its potential to reduce radiation-related pulmonary injury due to SBRT for lymph node negative (T1 to T3N0M0) peripheral or central localized (within 2cm of the proximal bronchial tree) NSCLC.
After an open-label, Phase 1, safety cohort of 5 subjects has been completed, a randomized, placebo-controlled Phase 2 portion of 66 subjects will be conducted.

开始日期2020-10-18

申办/合作机构

Galera Therapeutics, Inc.

NCT04555096

/ Terminated临床2期

A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)

A Trial of GC4419 in Patients with Critical Illness due to COVID-19

开始日期2020-09-09

申办/合作机构

Galera Therapeutics, Inc.

100 项与 Rucosopasem 相关的临床结果

登录后查看更多信息

100 项与 Rucosopasem 相关的转化医学

登录后查看更多信息

100 项与 Rucosopasem 相关的专利（医药）

登录后查看更多信息

项与 Rucosopasem 相关的文献（医药）

2025-03-01·Redox Biology

Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H2O2

Article

作者: Johnson, S T ; Sho, S ; Riley, D P ; Spitz, D R ; Buettner, G R ; Fath, M A ; Keene, J L ; Wagner, B A ; Caster, J M ; Solst, S R ; Kalen, A L ; George, B N ; Singhania, M ; Pulliam, C F ; Allen, B G ; Bayanbold, K ; Beardsley, R A

Differences in cancer and normal cell oxidative metabolism provide a unique therapeutic opportunity for developing combined modality approaches with redox-active small molecules as radio-chemosensitizers that are well-tolerated by normal tissues. Pentaazamacrocyclic Mn (II)-containing (MnPAM) superoxide dismutase (SOD) mimetics and pharmacological ascorbate given IV to achieve [mM] plasma levels (pharmacological ascorbate: P-AscH‾) have been shown to act individually as cancer cell radio- and chemosensitizers via the generation of H₂O₂in vivo. The current study shows that the combination of newly developed MnPAM dismutase mimetic, rucosopasem manganese (RUC) with P-AscH‾ radio-sensitizes non-small cell lung cancer cells (NSCLC) and increases steady state levels of intracellular H₂O₂ with no additional toxicity to normal human bronchial epithelial cells (HBECs). Conditional over expression of catalase (CAT) in H1299T CATc15 cells demonstrates that the combination of RUC and P-AscH‾ causes radio-sensitization through an H₂O₂-dependent mechanism. Interestingly, RUC combined with P-AscH‾ demonstrates more than additive cytotoxicity in both H1299T and A549 NSCLC cells, but conditional over-expression of ferritin heavy chain (FtH) protected only the H1299T, and not the A549, from this toxicity. Most importantly, the combination of RUC + P-AscH‾ was found to sensitize both H1299T and A549 cell types to radio-chemotherapy with cisplatin (CIS) + etoposide (ETOP). Finally, in H1299T NSCLC xenografts the combination of RUC + P-AscH‾ with CIS + ETOP and 12 × 2 Gy radiation significantly inhibits tumor growth and increased median overall over survival. These results support the hypothesis that selective MnPAM dismutase mimetic + P-AscH‾ enhances the efficacy of radio-chemotherapy in NSCLC through a mechanism governed by redox active metals and H₂O₂ production.

2024-03-01·Future oncology (London, England)

Stereotactic Body Radiotherapy Plus Rucosopasem in Locally Advanced or Borderline Resectable Pancreatic Cancer: GRECO-2 Phase II Study Design

Article

作者: Kurman, Michael ; Parikh, Parag J ; Hoffe, Sarah E ; Malafa, Mokenge P ; Kim, Dae Won ; Caster, Joseph M ; Aguilera, Todd A ; Costello, James ; Moser, Elizabeth C ; Kennedy, Eugene P ; Herman, Joseph M ; Terry, Kara ; Ghaly, Maged M

Ablative doses of stereotactic body radiotherapy (SBRT) may improve pancreatic cancer outcomes but may carry greater potential for gastrointestinal toxicity. Rucosopasem, an investigational selective dismutase mimetic that converts superoxide to hydrogen peroxide, can potentially increase tumor control of SBRT without compromising safety. GRECO-2 is a phase II, multicenter, randomized, double-blind, placebo-controlled trial of rucosopasem in combination with SBRT in locally advanced or borderline resectable pancreatic cancer. Patients will be randomized to rucosopasem 100 mg or placebo via intravenous infusion over 15 min, before each SBRT fraction (5 × 10 Gy). The primary end point is overall survival. Secondary end points include progression-free survival, locoregional control, time to metastasis, surgical resection rate, best overall response, in-field local response and acute and long-term toxicity.

2023-10-01·International journal of radiation oncology, biology, physics

Enhanced Peroxide Fluxes and Radiosensitization in Colorectal Tumors but Not Normal Enterocytes from the Combination of Superoxide Dismutase Mimetics and Pharmacological Ascorbate

Article

作者: Caster, J M ; Spitz, D R ; Michael, P ; Allen, B G ; George, B

PURPOSE/OBJECTIVE(S):

Selective superoxide dismutase mimetics (DMs), including GC4419 and GC4711, are radiation (RT) modulators which induce opposite effects in tumors and normal tissues and may be ideally suited for locally advanced rectal cancer. However, their tumor radiosensitization effect is limited at RT doses relevant to rectal cancer (2-5 Gy). Over this dose range, they protect normal mucosal tissues, but we and others have shown they do not reliably enhance tumor radiosensitization at doses < 8-15 Gy. We hypothesize that combining DMs and other therapies which also target redox metabolism may effectively sensitize tumors to clinically relevant RT doses for rectal cancer while maintaining their normal tissue sparing effects. Like DMs, pharmacological ascorbate (P-AscH) selectively increases lethal hydrogen peroxide (H₂O₂) fluxes in tumors, but it does so through distinct mechanisms which are potentially complimentary with DMs (particularly at low RT doses).

MATERIALS/METHODS:

Human HCT116, SW480, and HT29 colorectal tumor models and non-malignant FHs74 intestinal epithelial cells were used. Clonogenic survival was assessed following single-fraction RT (2-5 Gy) +/- P-AscH (5 pmol/cell) +/- GC4711 (20 µM). Dependency on H₂0₂ fluxes was tested by adding bovine catalase with drug and RT treatments. Oxygen consumption in culture media was measured using a Clark electrode. Rectal toxicity was assessed in vivo using IHC in fixed rectal tissues following fractionated, image-guided rectal RT (5-9 Gy x 3). Tumor growth delay was assessed following RT (5 Gy x 3) +/- P-AscH (4 g/kg) +/- GC4419 (10 mg/kg) in animals with unilateral HCT116 flank tumors.

RESULTS:

Combination therapy with P-AscH and GC4711 potently radiosensitized all tumor lines in vitro whereas neither agent significantly decreased clonogenic survival as a monotherapy. Neither drug nor combination treatment sensitized FHs74 epithelial cells. P-AscH increased oxygen consumption and H₂O₂ production in culture media and the addition of GC4711 significantly increased both more than P-AscH alone. Co-treatment with exogenous catalase inhibited cancer cell killing with combination therapy +/- RT. In vivo, combination therapy significantly enhanced tumor growth delay and survival. Both agents significantly decreased markers of acute rectal RT injury as monotherapies.

CONCLUSION:

Co-treatment with DMs and P-AscH selectively enhanced tumor radiosensitization by increasing oxygen consumption and H₂0₂ fluxes even in tumor models which are known to be resistant to oxidative stressors (HT29). In contrast, each agent conferred a radioprotective effect in the rectum. Combination therapy with DMs and P-AscH may represent a novel, potent approach to target dysregulated redox metabolism in colorectal tumors.

项与 Rucosopasem 相关的新闻（医药）

2025-10-22

·EndPoints

A trio of biotechs target $250M offerings; Regeneron stops cell therapy trial

Plus, news about AbbVie, Novartis, Analytical Biosciences, ENA Respiratory, VitriVax, Galera and Gilead: 👁️ Viridian Therapeutics launches $251M offering: The biotech is selling 11.4 million shares at $22.00 apiece. It plans to use the proceeds to support the launch of veligrotug, which is in pivotal trials for thyroid eye disease, and VRDN-003, which is the same drug but in subcutaneous form. — Jaimy Lee 💰 RAPT Therapeutics’s $250M stock sale: Earlier this week, the company said its partner Shanghai Jeyou Pharmaceutical plans to advance its anti-IgE antibody into Phase 3 trials in chronic spontaneous urticaria. It’s now selling about 8.3 million shares for $30.00 apiece. — Jaimy Lee 💵 Nurix Therapeutics also targets $250M offering: The company is selling 24.5 million shares for $10.21 per share as it advances bexobrutideg, its experimental treatment for chronic lymphocytic leukemia that just moved into pivotal trials. — Jaimy Lee 🧬 Regeneron ends study of cell therapy from 2seventy bio: The drugmaker pulled the plug on a Phase 1/2 trial of bbT369 in patients with certain forms of B cell non-Hodgkin lymphoma, according to the federal clinical trials database . The asset came from Regeneron’s purchase of 2seventy’s R&D infrastructure for $5 million upfront in 2024. The experimental autologous cell therapy targeted CD79a and CD20. — Kyle LaHucik 🧠 AbbVie pushes back Phase 2 trial for bipolar drug: The drug giant now expects a Phase 2 study for icalcaprant to wrap up in November 2027 versus prior guidance of October 2026, according to the federal clinical trials database. The study was slated to start in May but is now scheduled to start in February. The experimental medicine is a KOR antagonist that’s being tested as a treatment for bipolar disorder. Johnson & Johnson in March ended work on its Phase 3 drug in this class, while Neumora said in January that its KOR antagonist failed the first of three Phase 3 studies. — Kyle LaHucik 🧪 Novartis’ Cosentyx hits all Phase 3 targets in polymyalgia rheumatica: The Swiss drugmaker said the drug produced a “statistically significant and clinically meaningful” remission in patients with the inflammatory condition after one year. REPLENISH trial participants are either given two doses of Cosentyx or placebo, in combination with a steroid taper regimen over 24 weeks. Novartis now plans to submit the data to regulators in the first half of next year. — Jaimy Lee 💸 Analytical Biosciences’ $30M Series A: The Shanghai biotech, which disclosed the round on LinkedIn, plans to use the money to establish a newco and keep working on its biologics for cancer and autoimmune diseases. — Jaimy Lee 👃 ENA Respiratory raised $22.4M for viral defense spray : The biotech’s Series B round will fund a Phase 2 trial of a nasal spray designed to help the body fight viruses. Named INNA-051, the product is a TLR2/6 agonist that primes antiviral defenses in the nose, allowing the user to respond more quickly to viruses like colds, flu, RSV and coronaviruses, ENA said . Patients in the trial will take the drug once a week for up to three months, with ENA betting the spray will cut the number of cases, duration and severity of infections. New investors include the Gates Foundation and Flu Lab. Existing investors like Brandon Capital Partners, Uniseed and Stoic Venture Capital also participated. — Elizabeth Cairns 💉 VitriVax raises $17.25M in Series B: The company is developing a single-shot vaccine platform that won’t rely on a cold chain. The round was co-led by Adjuvant Capital and RA Capital. — Jaimy Lee 🧾 Galera sells certain cancer drugs for up to $105M: Biossil is spending $3.5 million upfront to buy Galera’s portfolio of dismutase mimetics, including avasopasem and rucosopasem. Galera could also get up to $105 million in milestones and contingent value rights. The biotech will focus on advancing its lead candidate, which is in Phase 2 development for metaplastic breast cancer. — Ayisha Sharma 📋 Gilead terminates Phase 1 of HIV drug: The company ended an early-stage trial of a long-acting injectable for people with HIV-1, according to the federal clinical trials database. The experimental medicine, known as GS-1219, was expected to be a twice-yearly candidate. HIV remains a core part of Gilead’s R&D and revenue. — Kyle LaHucik

临床2期临床3期疫苗免疫疗法细胞疗法

2025-10-22

·GlobeNewswire-Health Care

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera’s dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agreement includes 1) an upfront payment of $3.5 million, 2) potential future regulatory milestones, commercial milestones, and contingent value rights of up to $105 million. Biossil assumes all further obligations to Blackstone Life Sciences under the 2018 Amended and Restated Purchase and Sale Agreement (the Royalty Agreement) for dismutase mimetics products, notably a 4% royalty, should either of these agents reach commercialization. Galera’s lead program remains its pan-inhibitor of Nitric Oxide Synthase (NOS), which is in a multicenter Phase 2 trial in metaplastic breast cancer in combination with alpelisib and nab-paclitaxel. MALVERN, Pa, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (OTC: GRTX), a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics targeting cancer, today announced it has entered into an asset purchase agreement with Toronto-based biotech Biossil Inc, a privately held biotechnology company, for the acquisition of Galera’s dismutase mimetics portfolio, including avasopasem and rucosopasem. The agreement includes 1) an upfront payment of $3.5 million, and 2) potential future regulatory and commercial milestones, and contingent value rights of up to $105 million in aggregate. Biossil assumes all further obligations to Blackstone Life Sciences under Galera’s 2018 Amended and Restated Purchase and Sale Agreement (the Royalty Agreement) for dismutase mimetics products, notably a 4% royalty should avasopasem or rucosopasem reach commercialization. Galera’s lead program remains its pan-inhibitor of Nitric Oxide Synthase (NOS), L-NMMA or tilarginine, licensed from The Methodist Hospital of Houston, Texas (Houston Methodist), which is in a multicenter Phase 2 trial in metaplastic breast cancer in combination with alpelisib and nab-paclitaxel. The trial involved a lead-in to optimize the dose of alpelisib with this combination, which was completed at Houston Methodist, and enrollment is being expanded to two additional sites, the University of Texas MD Anderson Cancer Center and the National Institute of Health Clinical Center. In a 407-patient randomized double-blind phase 3 trial, avasopasem produced a statistically significant (p=0.045), 16% relative reduction in the incidence of severe oral mucositis (SOM) and a 56% relative reduction in SOM duration (p=0.002) in patients receiving standard-of-care chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer. The results of this trial will be published in the November 2025 (Vol 89) edition of eClinical Medicine and are now available online (Anderson Carryn et al. eClinicalMedicine, Volume 89, 2025). The FDA has granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Dismutase mimetics also have a well-developed mechanistic role in anti-cancer therapeutics in preclinical studies, and Galera completed a pilot trial of avasopasem combined with stereotactic body radiotherapy (SBRT) in patients with locally advanced pancreatic cancer (Taniguchi, Cullen M et al. The Lancet Oncology, Volume 24, Issue 12, 1387 – 1398 December 2023). “We are very pleased to enter into this agreement, which substantially increases the prospects for bringing avasopasem to patients with cancer,” said Mel Sorensen, M.D., President & CEO of Galera. “Biossil has the expertise and financing capable of advancing avasopasem through the remaining clinical and regulatory hurdles to make it available to patients with cancer. We also believe this transaction serves the best interests of our shareholders, who stand to benefit further should potential regulatory and commercial milestones be achieved. Galera will continue to focus on advancing its pan-NOS inhibitor for patients with advanced breast cancer.” “We thank the management team at Galera for entrusting Biossil with continued development of avasopasem,” said Dr. Alexander Mosa, M.D., PhD, Chief Scientific Officer, and Chair of Biossil. “Treatments to attenuate toxicity and improve the tolerability of chemoradiotherapy are urgently needed. Biossil will advance avasopasem with rigor commensurate with its clinical promise and the unmet need.” About Galera Therapeutics Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer. It was historically focused on developing avasopasem, a small molecule dismutase mimetic, in combination with chemoradiotherapy, to reduce the toxicities of the conventional regimens in patients with head and neck cancer. About Biossil Biossil is an AI-native drug development company advancing a pipeline of late-stage, first-in-class candidates for heterogeneous and life-threatening diseases. With teams in Toronto and Boston, and partnerships with leading academic medical centers and research hospitals, Biossil integrates proprietary AI with deep clinical and translational expertise to rescue and reposition promising clinical-stage assets. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning future clinical development activities and potential milestone payments. These forward-looking statements relate to us, our business prospects and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in Galera’s annual report on Form 10-K for the year ended December 31, 2024, and Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2025. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: Changes in capital resource requirements;Risks related to our inability to obtain sufficient additional capital to continue to advance our product candidates;Our and our collaborator’s ability to execute clinical programs for our product candidates;Results of clinical trials with our product candidates; andOur ability to obtain and maintain intellectual property rights and regulatory exclusivities. Investor Contact:Joel SussmanGalera Therapeutics, Inc.610-725-1517jsussman@galeratx.com

临床2期临床结果临床3期快速通道突破性疗法

2024-08-17

·生物制药小编

“半场开香槟”，现在破产清算

近日，Galera Therapeutics的董事会批准了一项破产清算计划，会将公司的员工人数削减至三人，同时评估其资产的可能出售方案，以及未来的破产清算事项。这家公司是近期又一家倒在了监管最终环节的Biotech。随着去年8月核心管线GC4419（avasopasem）被FDA拒批，该公司准备的商业化团队彻底失去了用武之地，如今正式走到了破产清算的一步。核心管线avasopasem的失利 Galera Therapeutics是专门开发超氧化物歧化酶模拟物的公司而该公司核心管线Avasopasem就是该技术的产物，开发用于减轻癌症患者（特别是头颈癌患者）在接受放射治疗时出现的严重口腔粘膜炎（SOM），并提高放射疗法的抗癌功效。最开始IIb期试验的反响非常不错，Avasopasem的数据表明其能显著缩短SOM的持续时间、降低其发生率和严重程度。因此也被FDA授予了突破性疗法和快速通道资格认定，用于减少放化疗诱发的SOM。但是非常蹊跷的是，2021年时，Avasopasem闹出了一个乌龙，这家公司先是宣布Avasopasem的III期ROMAN试验并未达到临床意义终点，后来又说经过进一步分析，说是CRO公司发现数据弄错了，纠正数据后，次要终点P值就得到了改善。可惜乌龙事件虽然当时改善了这家公司的股价（大涨96%），但是并未能影响FDA的评判的结果。毕竟主要终点的降低其实没达到统计学意义，想要只依靠次要终点来说服FDA显然有点难。而2023年8月时，FDA还是认为Avasopasem需要额外临床数据支撑其结果，因此发了一封CRL拒绝Avasopasem的上市，要求该公司给出额外数据。但显然，现金已经捉襟见肘的Galera Therapeutics并不可能做到这一要求。就算是暂停其他非核心管线rucosopasem的临床也无法履行FDA要求的额外临床要求。最有趣的是，这家公司甚至在被拒绝之前没预料到会被拒绝，2023年时还打算建立商业化团队，颇有一种半场“开香槟”，最终遭到翻盘的感觉。如今，这家账面只剩下约1000万美元的公司，除了资产清算外，似乎并没有其他选项。

突破性疗法临床3期放射疗法快速通道临床结果

100 项与 Rucosopasem 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不能切除性胰腺癌	临床2期	美国	Galera Therapeutics, Inc.	2021-05-07
不能切除性胰腺癌	临床2期	加拿大	Galera Therapeutics, Inc.	2021-05-07
不能切除性胰腺癌	临床2期	法国	Galera Therapeutics, Inc.	2021-05-07
不能切除性胰腺癌	临床2期	英国	Galera Therapeutics, Inc.	2021-05-07
非小细胞肺癌	临床2期	美国	Galera Therapeutics, Inc.	2020-10-18
新型冠状病毒感染	临床2期	美国	Galera Therapeutics, Inc.	2020-09-09
口腔炎	临床1期	美国	Galera Therapeutics, Inc.	2017-08-14
头颈部鳞状细胞癌	临床1期	美国	Galera Therapeutics, Inc.	2013-08-01
口腔鳞状细胞癌	临床1期	美国	Galera Therapeutics, Inc.	2013-08-01
口咽部鳞状细胞癌	临床1期	美国	Galera Therapeutics, Inc.	2013-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04698915 (CTgov)	临床2期	不能切除性胰腺癌	177	Drug GC4711 (Arm A Active GC4711)	齋憲製遞築鹽觸廠鬱製 = 壓窪蓋壓蓋餘網鏇窪鏇淵繭窪糧獵艱淵積廠獵 (齋顧鏇獵築襯鬱簾選鑰, 蓋鹽構鏇顧製襯膚築獵 ~ 製餘網鏇壓淵簾糧簾顧) 更多	-	2024-05-21
NCT04698915 (CTgov)	临床2期	不能切除性胰腺癌	177	Placebo (Arm B Placebo)	齋憲製遞築鹽觸廠鬱製 = 鏇齋鹽觸選艱鏇製壓廠淵繭窪糧獵艱淵積廠獵 (齋顧鏇獵築襯鬱簾選鑰, 構餘憲鑰範夢衊艱糧夢 ~ 鬱糧淵齋衊鏇選簾鹽齋) 更多	-	2024-05-21
NCT04476797 (GRECO-1, CTgov)	临床1/2期	非小细胞肺癌	47	GC4711	窪廠願鑰廠築鑰網鏇廠 = 選積齋齋窪淵鏇蓋糧顧網獵憲築齋鏇鹽艱願網 (鏇簾鏇餘餘壓蓋膚鏇膚, 獵鹹鏇範觸夢鑰餘選夢 ~ 鑰淵淵鏇遞網鬱齋範獵) 更多	-	2024-04-03
NCT04476797 (GRECO-1, GlobeNewswire) 人工标引	临床1期	非小细胞肺癌	7	SBRT+rucosopasem	齋遞鹹繭夢顧構窪選壓(夢繭獵積襯衊淵範淵遞) = 積築積膚鏇觸繭製衊繭觸鏇糧齋膚鹽膚糧夢構 (鬱糧齋簾艱衊艱夢觸範 )	积极	2022-06-29
NCT04555096 (CTgov)	临床2期	新型冠状病毒感染	16	GC4419 (Active GC4419)	壓獵範繭衊鏇鬱鬱艱製 = 艱齋廠壓艱鏇餘鏇範選餘鑰壓觸製製蓋觸鏇範 (膚廠夢獵衊餘醖遞夢艱, 遞餘膚襯壓夢簾鹹蓋簾 ~ 齋廠鹹蓋鏇簾憲網願範) 更多	-	2022-03-18
NCT04555096 (CTgov)	临床2期	新型冠状病毒感染	16	Placebo (Placebo)	壓獵範繭衊鏇鬱鬱艱製 = 廠壓網壓窪範鹹選衊襯餘鑰壓觸製製蓋觸鏇範 (膚廠夢獵衊餘醖遞夢艱, 繭築鏇齋鏇製窪獵鹹製 ~ 製積鹹鏇淵壓糧夢廠獵) 更多	-	2022-03-18